Overview

Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension

Status:
NOT_YET_RECRUITING
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH. At least 20 and up to approximately 30 participants will be enrolled and receive JK07 high dose in this open-label trial.
Phase:
PHASE2
Details
Lead Sponsor:
Salubris Biotherapeutics Inc